Abstract
Recurrent and unpredictable episodes of vaso-occlusion are the hallmark of sickle cell disease. Symptomatic management and prevention of these events using the fetal hemoglobin-reactivating agent hydroxyurea are currently the mainstay of treatment. Discoveries over the past 2 decades have highlighted the important contributions of various cellular and soluble participants in the vaso-occlusive cascade. The role of these elements and the opportunities for therapeutic intervention are summarized in this review.
Original language | English (US) |
---|---|
Pages (from-to) | 362-369 |
Number of pages | 8 |
Journal | Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program |
Volume | 2013 |
DOIs | |
State | Published - 2013 |
Externally published | Yes |
ASJC Scopus subject areas
- Hematology